Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study

Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study

Abstract Background Real‐world evidence on immune‐related adverse events (irAEs) are relatively insufficient. Herein patterns and outcomes of irAEs after administration of anti‐programmed cell death 1 (PD‐1) and its legend 1 (PD‐L1) antibodies were investigated. Methods Patients treated with anti‐PD...

Full description

Bibliographic Details
Main Authors: Xiaoxiao Ge, Weiping Jiang, Hongqing Li, Yanxu Wu, Xiangyang Li, Shaohua Cui
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
immune‐related adverse events
immunotherapy
solid tumor
survival
Online Access:https://doi.org/10.1002/cam4.6449

Internet

https://doi.org/10.1002/cam4.6449

Similar Items